-
Multi-service mobile app platform brings together doctors, laboratories & diagnostics, pharmacies, and insurance for a one-stop cashless and seamless outpatient user experience
-
The company's revenues increased by 11.4 per cent year-on-year to Rs 4,919.4 crore in Q1FY22 from Rs 4,728.4 crore in Q1FY21.
-
Demand for Covid pandemic-related drugs will continue to drive the growth momentum this fiscal
-
Soft launch of Sputnik V vaccine reaches over 50 cities and towns, after initial launch in Hyderabad on May 14
-
On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply the drug for the treatment of Covid-19 in India
-
With the Maximum Retail Price (MRP) of each sachet fixed at Rs 990, the drug will be supplied to major governments as well as private hospitals across the country, said an official release.
-
Being a limited pilot phase presently, registration on CoWIN is not open yet to public, but will become open at the time of commercial launch.
-
In addition to storage, Rockwell will provide end-to-end logistics and after sales service support for the vaccine freezers across India
-
The Hyderabad-based drug major is voluntarily recalling the affected lots of the drug in 10 mg strength due to “failed impurities degradation specifications”.
-
The drug maker's growth would be primarily driven by organic moves, focusing around pipeline monetisation, productivity enhancement, diversifications.
-
The drug can be added as a supplement or adjunct to the existing treatment protocols to treat moderate to severe Covid patients
-
So far, Dr Reddy’s has received the first consignment of 1.5 lakh doses on May 1 with imported supplies of the first dose.
-
Pilot programme to administer from the first batch of 1,50,000 doses of Sputnik V vaccines imported from RDIF
-
Plan to vaccinate 125 million people in the next 8-12 months across the country
-
For FY21, the company posted a consolidated net profit of Rs 1,952 crore as against Rs 2,026 crore in 2019-20.
-
To manufacture and commercialise baricitinib in India, approved for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults
-
The latest therapy with links to the city is the glucose molecule 2-DG and its anti-Covid-19 therapeutic application that was given a green signal by Indian drug regulatory authorities
-
The drug has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO).
-
Hyderabad-based Dr Reddy’s Laboratories has collaborated with RDIF to import the first consignment of Sputnik-V while it is expected that the pharma giant will start manufacturing from its local facilities in India
-
India has become the 60th country to approve Sputnik V, RDIF, Russia's sovereign wealth fund, said in a statement.